Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data
After a negative FDA advisory committee vote, Capricor Therapeutics said it will file additional data and analyses on its Duchenne muscular dystrophy therapy in hopes of a better shot at potential approval in a narrower ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.